A Pharmacist's Guide to Reducing the Burden of Influenza: Current Prevention and Treatment Strategies

A Pharmacist's Guide to Reducing the Burden of Influenza: Current Prevention and Treatment Strategies

Activity Details
  • Credit Amounts:
    • CPE: 1.00
    • Other: 1.00
  • Cost: Free
  • Release: Sep 15, 2017
  • Expires: Sep 15, 2018
  • Estimated Time to Complete:
    1 Hour(s)
  • System Requirements:
  • Average User Rating:
    (2 Ratings)

Faculty

Michael D.  Hogue Michael D. Hogue, PharmD, FAPhA, FNAP
Associate Dean, Center for Faith and Health
Samford University College of Health Sciences
Professor, Pharmacy
Samford University McWhorter School of Pharmacy
Birmingham, Alabama

Needs Statement

Pharmacists must take a proactive role in preventing and managing influenza for their patients, particularly those at higher risk of serious complications from infection. With the expansion of available influenza vaccines, selecting the most appropriate vaccine can be confusing.

This activity is designed to increase the competence of pharmacists in the prevention and management of influenza to effectively and safely manage patients with influenza.

Target Audience

Pharmacists in all clinical settings including acute care institutions, outpatient clinics, and community pharmacies

Objectives

Upon completion of this education activity, participants will be able to:

  • Differentiate among the currently available influenza vaccines
  • Select an appropriate vaccine based on patient factors and preferences
  • Discuss strategies aimed to increase influenza vaccination rates
  • Improve acceptance of immunization by patients in various clinical settings
  • Identify patients at risk of influenza-associated complications and mortality
  • Initiate appropriate antiviral therapy to minimize the burden of disease

Accreditation

CPE
ACPEThe University of Kentucky College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge-based activity has been assigned UAN 0022-9999-17-149-H06-P and will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

Statements of participation will indicate hours and CEUs based on participation and will be issued online at the conclusion of the activity. Successful completion includes completing the activity, its accompanying evaluation and/or posttest (score 70% or higher) and requesting credit online at the conclusion of the activity. Credit will be uploaded to CPE Monitor, and participants may print a statement of credit or transcript from their NABP e-profile. The College complies with the Accreditation Standards for Continuing Pharmacy Education.

Other
UK Healthcare CECentral certifies this activity for 1.00 hour of participation.

Faculty Disclosure

Michael D. Hogue, PharmD, FAPhA, FNAP - Speaker - has relevant financial relationships with commercial interests as follows:
Merck & Co - Principle Investigator - Receives grant funding
Pfizer - Speakers Bureau - Receives speaking fee

No planners have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

This activity is jointly provided by the University of Kentucky and Vemco MedEd.

Supported by an unrestricted educational grant from Sanofi Pasteur.

CE Content Concerns

Policy

Concerns or complaints related to ACPE or ACCME standards may be submitted in writing to the Director of UK HealthCare CECentral by fax to 859-323-2920, or by mail to 2365 Harrodsburg Road, Ste B475, Lexington, KY 40504

Procedures

  • The Director or his/her designee will review, investigate, forward and/or respond to complaints and will put forth a best effort to adjudicate the issue(s), along with CECentral staff members, within two (2) weeks of receipt of the grievance or complaint.
  • If needed, concerns, complaints, or grievances will be brought before the UK HealthCare CECentral Advisory Board.
  • Issues regarding activity content also will be reviewed and addressed by the Activity Director.
  • A written decision will be issued in a timely manner by the Director of UK HealthCare CECentral or his/herdesignee.
  • Grievances will be considered when planning future activities.

Appeal Procedure

  • Persons who wish to appeal a decision should address the appeal by email, fax or in writing to the Director of UK HealthCare CECentral within two (2) weeks of receipt of the response.
  • The Director will bring the appeal to the UK HealthCare CECentral Advisory Board.
  • The results of the appeal will be sent to the participant no later than two (2) weeks following the meeting of the board.